The aim of this study is to determine the ED90 of hyperbaric intrathecal bupivacaine for the super obese population undergoing cesarean section under a combined spinal epidural technique.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
45
Determination of the dose will rely on the outcomes of the preceding 7 patients receiving the same dose, as the number of previous patients to consider is a function of the target dose. Among all patients who received a certain dose, a proportion of successful outcomes will be determined (P(d)); if P(d) \<0.90, and at least one of the previous 7 patients who received the same dose had an unsatisfactory outcome, the next patient will receive a pre-determined increment of 0.75 mg of bupivacaine. Alternatively, if P(d) 0.90 and the previous 7 patients who received the same dose had successful outcomes, the next patient will receive a pre-determined decrement of 0.75mg of bupivacaine. Otherwise, the dose will remain the same.
Duke University Hospital
Durham, North Carolina, United States
Number of Participants With Successful Blocks for Induction (Success Induction)
Bilateral T6 sensory level to pinprick
Time frame: 10 minutes after intrathecal drug administration
Number of Participants With Successful Blocks for Operation (Success Operation)
Successful initial sensory level without requiring additional epidural anesthetic
Time frame: during surgery up to 90 minutes after intrathecal injection
ED90 (90% Effective Dose) of Intrathecal Bupivacaine for Cesarean Delivery
Time frame: 90 minutes
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.